Dr. Reddy Laboratories
Dr. Reddy Laboratories has a production facility at Pydibheemavaram in Srikakulam. The unit is set up in an area of 79.46 acres. The company has invested Rs 2480 million in in its unit in Srikakulam.
The Dr. Reddy's unit in Srikakulam makes APIs (Active Pharmaceutical Ingredient) for foreign export, including Bromfenacna, Celecoxib, Ibuprofen, Ketorolac Tromethamine, Naproxen, Naproxen Sodium, Glimeprid, Linagliptin, Liraglutide and Nateglinide.
On November 9, 2015 it was reported that FDA, the US regulator, has found fault with API (Active Pharmaceutical Ingredient) production facilities in Srikakulam, Miryalguda and Duvvada in Visakhapatnam. The FDA conducted inspections in November 2014.